Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial - Yardley, Denise; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, Andreas; de la Cruz-Merino, L.; et al. (Annals of oncology, 2018)
Im Titel erscheint "nab" klein geschrieben und schräg gestellt